ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,307.93
-0.50%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.4955
0.06%
Brent Oil
82.04
-0.10%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) ニュース

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:ALLR
日付受信時刻ニュースソース見出しコード企業名
2024/06/0621 : 54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/2421 : 55Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/2121 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/2021 : 00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/1805 : 08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/1522 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/1505 : 45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/1505 : 01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/1000 : 21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0922 : 47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0905 : 05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0722 : 30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0622 : 29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0622 : 13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0621 : 00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
2024/05/0221 : 00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
2024/04/2920 : 00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
2024/04/1722 : 10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
2024/04/0422 : 15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/2721 : 30GlobeNewswire Inc.Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/2520 : 30GlobeNewswire Inc.Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0822 : 38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0821 : 15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0821 : 15GlobeNewswire Inc.Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0811 : 45Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0506 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/03/0123 : 21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
2024/02/2820 : 00GlobeNewswire Inc.Allarity Therapeutics to Present at Biomarkers 2024NASDAQ:ALLRAllarity Therapeutics Inc
2024/02/2406 : 09Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:ALLRAllarity Therapeutics Inc
2024/02/1423 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLR

最近閲覧した銘柄

USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
NASDAQ
TSLA
Tesla
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
CCOM
SILVER
SILVER
FX
USDEUR
US Dollar vs Euro
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有